Fujifilm Toyama Chemical’s US-based Phase II trial investigating Avigan (favipiravir) in hospitalised Covid-19 patients has recruited 20% of its patient target, with the aim to close enrolment this month, a source said.
On 15 April, the company announced it expanded its manufacturing capacity for Avigan, expecting up to 100,000 treatment courses to be available by July. Read more here.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
